GYRE Gyre Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 7, 2026GYRE Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
GYRE Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 31 de Outubro de 2023 | 1-for-15 | Reverso |
| 13 de Fevereiro de 2017 | 1-for-15 | Reverso |
| 21 de Agosto de 2015 | 1-for-7 | Reverso |
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | GYRE | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | -35.5média 5A ≈167.4 | ≈167.4 | · | · | |
| P/S (TTM) | 6.3média 5A ≈8.9 | ≈8.9 | 8.0 | Subvalorizado | |
| P/B (MRQ) | 7.0média 5A ≈-28.9 | ≈-28.9 | 3.2 | Sobreavaliado | |
| Preço / FCF (TTM) | -47.9média 5A ≈-1214.5 | ≈-1214.5 | · | · | |
| Preço / Fluxo de Caixa (TTM) | -52.0média 5A ≈104.6 | ≈104.6 | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | 7.3média 5A ≈10.1 | ≈10.1 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | GYRE | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | -14.0%média 5A ≈-11.4% | ≈-11.4% | -1043.3% | Primeira linha | |
| Margem EBITDA (TTM) | -11.1%média 5A ≈-9.9% | ≈-9.9% | -1043.3% | Primeira linha | |
| Margem de Impostos Pré-Tributação (TTM) | -13.5%média 5A ≈-11.2% | ≈-11.2% | · | · | |
| Margem de Lucro Líquido (TTM) | -23.7%média 5A ≈-16.7% | ≈-16.7% | -989.0% | Primeira linha | |
| ROA (TTM) | -16.1%média 5A ≈-20.7% | ≈-20.7% | -33.0% | Primeira linha | |
| ROE (TTM) | -28.3%média 5A ≈65.0% | ≈65.0% | -39.4% | Primeira linha | |
| ROIC | 7.4%média 5A ≈135.1% | ≈135.1% | -32.0% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | GYRE | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 4.3média 5A ≈3.4 | ≈3.4 | 11.3 | Baixa liquidez | |
| Índice de Liquidez Seca (MRQ) | 3.0média 5A ≈2.5 | ≈2.5 | 6.6 | Baixa liquidez |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | GYRE | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 10.2%média 5A ≈248.7% | ≈248.7% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 4.5%média 5A ≈74.5% | ≈74.5% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 41.0% | · | · | · | |
| EPS YoY | -60.0% | · | · | · | |
| Net Income YoY (Lucro Líquido Ano a Ano) | -44.8% | · | · | · | |
| EPS CAGR 3Y (CAGR de LPA 3A) | -12.6% | · | · | · | |
| Net Income CAGR 3Y (CAGR de Lucro Líquido 3A) | 31.8% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | GYRE | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.8média 5A ≈0.9 | ≈0.9 | 0.0 | Primeira linha | |
| Receivables Turnover (Giro de Contas a Receber) | 4.6 | · | · | · | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$186.5K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
| Data ex | Valor | Moeda | Rendimento |
|---|---|---|---|
| Jan 13, 2023 | $3,60 | USD | ≈642.3% |
| Set 21, 2022 | $21,45 | USD | ≈286.0% |
| Ago 20, 2015 | $896,18 | USD | ≈59.3% |
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 18, 2026 | $-0.12 | $-0.09 | -30.7% |
| 31 de Março de 2026 | Mai 8, 2026 | $-0.10 | $-0.07 | -33.7% |
| 31 de Dezembro de 2025 | $0.05 | $0.06 | -13.5% | |
| 30 de Setembro de 2025 | $0.08 | $0.03 | 194.1% | |
| 30 de Junho de 2025 | $0.02 | $0.03 | -34.6% | |
| 31 de Março de 2025 | $0.03 | $0.03 | -2.0% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $117M | $106M | $113M | $102M | $7M | $21M | · | $6.0K | $1M | · | · | $275.0K | |
| Cost of Revenue | $5M | $4M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Gross Profit | · | $102M | $109M | $97M | · | · | · | · | · | · | · | · | |
| R&D Expense | $14M | $12M | $14M | · | $69M | $53M | $44M | $21M | $13M | $12M | $6M | $5M | |
| SG&A Expense | $21M | $16M | $15M | $17M | $19M | $16M | $13M | $12M | $10M | $9M | $10M | $4M | |
| Operating Expenses | $105M | $90M | $176M | $88M | $95M | $78M | $57M | $34M | $23M | $21M | $16M | $9M | |
| Operating Income | $11M | $16M | $-67M | $9M | $-88M | $-57M | $-57M | $-34M | $-22M | $-20M | $-14M | $-8M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | $1M | $23.0K | |
| Other Non-op | $-2M | $-2M | $-2M | · | $-78.0K | $-91.0K | $-39.0K | $2M | $-1.0K | $86.0K | $131.0K | $575.0K | |
| Pretax Income | $14M | $23M | $-77M | $9M | $-88M | · | · | · | · | · | · | $-29M | |
| Income Tax | $5M | $5M | $9M | $5M | · | · | · | · | · | · | · | $3M | |
| Net Income | $10M | $18M | $-85M | $4M | $-88M | $-56M | $-55M | $-30M | $-22M | $-17M | $-15M | $-7M | |
| EPS (Basic) | $0.06 | $0.14 | $-1.41 | $0.04 | $-2.87 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 | · | · | · | · | · | · | · | |
| Shares (Basic) | 89,344,622 | 85,094,948 | 65,831,675 | 63,588,119 | 30,640,977 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 103,180,037 | 102,293,526 | 65,831,675 | 75,686,406 | 30,640,977 | · | · | · | · | · | · | · | |
| EBITDA | $14M | $18M | $-66M | $-8M | · | $-57M | $-57M | · | $-22M | $-20M | $-13M | $-29M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $49M | $12M | $34M | $25M | $44M | $30M | $15M | $31M | $14M | $10M | $29M | $2M | |
| Short-term Investments | $15M | $15M | · | · | $3M | $49M | $61M | $89M | $18M | $7M | $3M | $51M | |
| Receivables | $31M | $20M | $15M | · | $2M | $3M | $15M | · | · | · | · | $141.0K | |
| Inventory | $10M | $6M | $4M | $6M | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $10M | $3M | · | $2M | $3M | $7M | $4M | $4M | $1M | $958.0K | $2M | $103.0K | |
| Other Current Assets | $1M | $1M | $1M | $843.0K | · | · | · | · | · | · | · | · | |
| Current Assets | $149M | $65M | $57M | $50M | $51M | $90M | $96M | $124M | $39M | $38M | $69M | $2M | |
| PP&E (Net) | $28M | $24M | $23M | $18M | $970.0K | $433.0K | $304.0K | $386.0K | $276.0K | $444.0K | $698.0K | $911.0K | |
| PP&E (Gross) | $39M | $29M | $28M | $22M | · | · | · | $671.0K | $2M | $2M | $6M | $8M | |
| Accum. Depreciation | $11M | $6M | $4M | $4M | · | · | $400.0K | $300.0K | $2M | $2M | $6M | $7M | |
| Intangibles | $5M | $273.0K | $273.0K | $297.0K | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $8M | $3M | $995.0K | $3M | $472.0K | $528.0K | $257.0K | $543.0K | $128.0K | · | · | $12.0K | |
| Total Assets | $220M | $125M | $117M | $85M | $56M | $95M | $99M | $125M | $40M | $38M | $70M | $3M | |
| Accounts Payable | $1M | $108.0K | $355.0K | $122.0K | $6M | $6M | $4M | $1M | $747.0K | $837.0K | $939.0K | $249.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Current Liabilities | $24M | $20M | $20M | $12M | $14M | $18M | $29M | $5M | $9M | $22M | $38M | $2M | |
| Capital Leases | $2M | $885.0K | $199.0K | $121.0K | $408.0K | $981.0K | $1M | · | · | · | · | · | |
| Other Non-current Liabilities | $2M | $7.0K | $49.0K | $55.0K | · | · | · | · | · | · | · | · | |
| Total Liabilities | $31M | $27M | $38M | $13M | $15M | $19M | $30M | $5M | $9M | $22M | $38M | $3M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Common Stock | $91.0K | $86.0K | $77.0K | $64.0K | $31.0K | $22.0K | $12.0K | $12.0K | $6.0K | $1.0K | $1.0K | $34.0K | |
| Paid-in Capital | $173M | $136M | $68M | $33M | $444M | $391M | $327M | $323M | $204M | $164M | $162M | $7M | |
| Retained Earnings | $-113M | $-73M | $-86M | $7M | $-403M | $-315M | $-259M | $-203M | $-173M | $-148M | $-131M | $-116M | |
| AOCI | $-908.0K | $-3M | $-2M | $-392.0K | · | $5.0K | $34.0K | $-4.0K | · | $-1.0K | $1.0K | $4.0K | |
| Stockholders' Equity | $62M | $63M | $-16M | $43M | $41M | $76M | $68M | $120M | $31M | $16M | $31M | $-109M | |
| Liabilities + Equity | $220M | $125M | $117M | $85M | $56M | $95M | $99M | $125M | $40M | $38M | $70M | $3M | |
| Shares Outstanding | 91,314,007 | 86,307,544 | 76,595,616 | 63,588,119 | 31,409,707 | 22,097,820 | 12,040,835 | 11,954,528 | 6,081,230 | 801,756 | 762,005 | 370,944 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $1M | $290.0K | $138.0K | $146.0K | $149.0K | $173.0K | $389.0K | $470.0K | $680.0K | |
| Stock-based Comp | $7M | $831.0K | $7M | $13M | $3M | $4M | $3M | $3M | $863.0K | $635.0K | $326.0K | $244.0K | |
| Deferred Tax | $-1M | $-1M | $-834.0K | $-890.0K | · | · | · | · | · | · | · | $72.0K | |
| Amort. of Intangibles | $576.0K | $38.0K | $100.0K | $200.0K | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | $1M | $4M | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-17M | $-23M | $104M | $-26M | · | $-3M | $8M | · | $585.0K | $-3M | $-5M | $-6M | |
| Operating Cash Flow | $1M | $-4M | $26M | $11M | $-84M | $-55M | $-44M | $-29M | $-20M | $-18M | $-19M | $-6M | |
| CapEx | $1M | $2M | $9M | $5M | $839.0K | · | $64.0K | $376.0K | $23.0K | $468.0K | $272.0K | $4.0K | |
| Investing Cash Flow | $-474.0K | $-20M | $-20M | $-14M | $48M | $10M | $27M | $-71M | $-11M | · | · | · | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | $-1M | |
| Stock Issued | · | $773.0K | · | · | · | · | · | · | $5M | $958.0K | · | $296.0K | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | $82.0K | · | |
| Net Stock Activity | · | $773.0K | · | · | · | · | · | · | $5M | $958.0K | $-82.0K | $296.0K | |
| Dividends Paid | · | · | · | $45M | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $24M | $2M | $2M | $-45M | $50M | $60M | $327.0K | $111M | $21M | · | · | · | |
| Net Change in Cash | $25M | $-22M | $8M | $-5M | $14M | $15M | $-16M | $11M | $-10M | $-19M | $28M | $-1M | |
| Taxes Paid | $6M | $9M | $6M | $6M | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-180.0K | $-6M | $17M | · | · | · | $-44M | · | $-20M | $-19M | $-19M | $-34M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | $-35M |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 96.3% | 95.9% | · | · | · | · | · | · | · | · | · | |
| Operating Margin | 9.8% | 15.3% | -59.3% | · | · | -273.9% | · | · | · | · | · | -10805.1% | |
| Net Margin | 8.5% | 16.9% | -75.3% | · | · | -268.5% | · | · | · | · | · | -11862.9% | |
| Pretax Margin | 12.4% | 21.9% | -67.8% | · | · | · | · | · | · | · | · | -10596.0% | |
| EBITDA Margin | 12.0% | 16.8% | -58.3% | · | · | -273.2% | · | · | · | · | · | -10677.5% | |
| ROA | 6.8% | 14.8% | -84.9% | -19.6% | · | -58.2% | -49.4% | · | -55.6% | -31.5% | -40.7% | -25.3% | |
| ROE | 11.7% | 75.4% | 387.3% | -214.5% | · | -66.1% | -73.8% | · | -92.0% | -71.4% | 37.9% | -1073.6% | |
| ROIC | 7.4% | 19.7% | 471.8% | 41.4% | · | · | · | · | · | · | · | -30.5% |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.6 | 3.3 | 2.9 | 1.7 | · | 5.0 | 3.3 | · | 4.5 | 1.7 | 1.8 | 37.1 | |
| Quick Ratio | 4.6 | 2.4 | 1.7 | 1.3 | · | 4.6 | 3.2 | · | 3.7 | 0.8 | 0.9 | 36.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | -9.3 | -1291.9 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.9 | 1.1 | · | · | 0.2 | · | · | · | · | · | 0.0 | |
| Inventory Turnover | · | 0.7 | 0.9 | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.6 | 6.1 | · | · | · | 2.3 | · | · | · | · | · | 1.3 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.16 | $0.73 | $-0.21 | $-0.57 | · | $3.44 | $5.68 | · | $5.06 | $20.04 | $2.75 | $3.23 | |
| Revenue / Share | $1.13 | $1.03 | $1.72 | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.01 | $-0.04 | $0.39 | $-1.05 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.41 | $0.14 | $0.44 | $0.57 | · | $1.37 | $1.28 | · | $2.38 | $12.80 | $2.55 | $1.67 | |
| Dividend / Share | · | · | · | $0.24 | · | · | · | · | · | · | · | · | |
| Dividend Paid / Share | · | · | · | $1.43 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 | $-1.46 | $-1.46 | $-1.46 | $-1.46 | $-1.46 | $-1.46 | $-1.46 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.2% | -6.8% | 10.9% | 1294.0% | -65.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 4.5% | 143.4% | 75.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -60.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -12.6% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -44.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 31.8% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $106M | $113M | $102M | $7M | $21M | · | $6.0K | $1M | $248.0K | $248.0K | $275.0K | |
| Net Income TTM | $10M | $18M | $-85M | $4M | $-88M | $-56M | $-55M | $-30M | $-22M | $-17M | $-15M | $-7M | |
| Market Cap | $645M | $1.04B | $1.97B | $300M | · | $2.09B | $1.23B | · | $1.24B | $117M | $8.05B | $139.98B | |
| P/E | 353.0 | 242.0 | -18.2 | 265.0 | -4.8 | -64.8 | -70.0 | -81.1 | -140.1 | -100.2 | -482.4 | -2837.2 | |
| P/S | 5.5 | 9.9 | 17.3 | 2.9 | · | 99.8 | · | · | 1222.2 | 472.8 | 32458.2 | 509025.8 | |
| P/B | 6.1 | 16.5 | -124.3 | -13.8 | · | 27.5 | 18.0 | · | 40.4 | 7.3 | 256.2 | 1283.2 | |
| P / Tangible Book | 6.4 | 16.6 | · | 7.1 | 10.4 | 27.5 | · | · | · | · | · | · | |
| P / Cash Flow | 638.3 | -286.8 | 76.0 | -9.1 | · | -38.0 | -28.2 | · | -62.4 | -6.3 | -421.1 | -4059.5 | |
| P / FCF | -3581.5 | -175.3 | 113.3 | · | · | · | -28.2 | · | -62.3 | -6.2 | -415.1 | -4059.0 | |
| Dividend Yield | · | · | · | 15.0% | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.28% | 0.41% | -5.5% | 0.38% | -21.0% | -1.5% | -1.4% | -1.2% | -0.71% | -1.0% | -0.21% | -0.04% | |
| Payout Ratio | · | · | · | -546.4% | · | · | · | · | · | · | · | · | |
| Annual Payout | · | · | · | $45M | · | · | · | · | · | · | · | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $23M | $37M | $31M | $30M | $22M | $28M | $25M | $25M | $27M | $27M | $32M | $29M | $25M | · | · | |
| Cost of Revenue | $2M | $1M | $2M | $2M | $1M | $894.0K | $1M | $958.0K | $770.0K | $979.0K | $1M | $1M | $1M | $1M | · | · | |
| Gross Profit | · | · | · | $29M | $26M | $21M | · | $25M | $24M | $26M | $26M | $31M | $28M | $24M | · | · | |
| R&D Expense | · | $7M | $5M | $2M | $8M | $3M | $4M | $3M | $3M | $2M | $5M | $3M | $4M | $3M | · | $803.0K | |
| SG&A Expense | $8M | $7M | $7M | $4M | $7M | $5M | $5M | $4M | $3M | $3M | $10M | $1M | $2M | $2M | $4M | $4M | |
| Operating Expenses | $43M | $32M | $41M | $22M | $32M | $20M | $30M | $20M | $21M | $18M | $118M | $18M | $23M | $17M | $119M | $5M | |
| Operating Income | $-14M | $-9M | $118.0K | $7M | $-2M | $2M | $665.0K | $4M | $3M | $8M | $-92M | $13M | $5M | $7M | $-22M | $-5M | |
| Other Non-op | $-943.0K | $29.0K | $-2M | $727.0K | $-488.0K | $107.0K | $-2M | $-75.0K | $-72.0K | $122.0K | $-237.0K | $-1M | $629.0K | · | · | $-1.0K | |
| Pretax Income | $-14M | $-9M | $-66.0K | $8M | $-2M | $5M | $772.0K | $4M | $6M | $12M | $-100M | $11M | $6M | $6M | $-23M | $-5M | |
| Income Tax | $-164.0K | $621.0K | $1M | $2M | $662.0K | $901.0K | $203.0K | $1M | $1M | $3M | $699.0K | $4M | $2M | $2M | $5M | $0 | |
| Net Income | $-14M | $-19M | $-1M | $6M | $-2M | $5M | $569.0K | $3M | $5M | $10M | $-101M | $8M | $4M | $4M | $-28M | $-5M | |
| EPS (Basic) | $-0.12 | $-0.10 | $-0.01 | $0.04 | $-0.02 | $0.03 | $0.00 | $0.01 | $0.04 | $0.09 | $-1.54 | $0.06 | $0.03 | $0.04 | $-0.98 | $-0.16 | |
| EPS (Diluted) | $-0.12 | $-0.10 | $-0.01 | $0.03 | $-0.03 | $0.00 | $0.00 | $0.01 | $0.01 | $0.03 | $-1.51 | $0.05 | $0.02 | $0.03 | $-0.99 | $-0.16 | |
| Shares (Basic) | 100,637,599 | 91,317,142 | · | 90,850,040 | 89,119,344 | 86,420,530 | · | 85,643,646 | 85,502,403 | 83,265,879 | · | 63,588,119 | 63,588,119 | 63,588,119 | · | 31,484,542 | |
| Shares (Diluted) | 100,637,599 | 91,344,584 | · | 103,971,546 | 89,203,138 | 101,970,672 | · | 102,640,373 | 102,205,888 | 102,594,197 | · | 78,904,324 | 78,904,324 | 78,921,366 | · | 31,484,542 | |
| EBITDA | · | $-9M | · | $7M | $2M | $3M | · | $4M | $3M | $8M | · | $-2M | $-3M | $181.0K | · | $-5M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $38M | $37M | $40M | $36M | $15M | $12M | $16M | $16M | $30M | $34M | $2M | $7M | $8M | $25M | $23M | |
| Short-term Investments | $14M | $12M | $15M | $20M | $18M | $15M | $15M | $9M | $9M | $8M | · | · | · | · | · | · | |
| Receivables | $28M | $23M | $31M | $26M | $25M | $20M | $20M | · | · | · | $15M | · | · | · | · | · | |
| Inventory | $11M | $11M | · | · | $9M | $8M | · | $6M | $6M | $5M | $4M | · | · | · | $6M | · | |
| Prepaid Expense | $8M | $4M | · | $3M | $3M | $8M | · | · | · | · | · | · | $697.0K | $915.0K | · | $2M | |
| Other Current Assets | · | · | $1M | · | · | · | $1M | $2M | $2M | $2M | $1M | · | · | · | $843.0K | · | |
| Current Assets | $122M | $92M | $102M | $99M | $91M | $68M | $65M | $55M | $54M | $63M | $57M | $5M | $8M | $14M | $50M | $30M | |
| PP&E (Net) | $27M | $24M | $24M | $24M | $23M | $24M | $24M | $24M | $24M | $24M | $23M | · | · | $1.0K | $18M | $124.0K | |
| PP&E (Gross) | $40M | $32M | $31M | $31M | $30M | $30M | $29M | $30M | $28M | $28M | $28M | · | · | · | $22M | · | |
| Accum. Depreciation | $13M | $8M | $8M | $7M | $6M | $6M | $6M | $5M | $5M | $5M | $4M | · | · | · | $4M | · | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $273.0K | $184.0K | $186.0K | $196.0K | $205.0K | · | · | · | $297.0K | · | |
| Other Non-current Assets | $7M | $5M | $2M | $5M | $5M | $6M | $3M | $3M | $1M | $802.0K | $995.0K | $168.0K | $168.0K | $168.0K | $3M | $168.0K | |
| Total Assets | $199M | $162M | $166M | $159M | $153M | $130M | $125M | $125M | $121M | $122M | $117M | $10M | $12M | $19M | $85M | $31M | |
| Accounts Payable | $1M | $265.0K | $124.0K | $556.0K | $71.0K | $122.0K | $108.0K | $303.0K | $271.0K | $330.0K | $355.0K | $158.0K | $5.0K | $16.0K | $122.0K | $41.0K | |
| Current Liabilities | $29M | $20M | $18M | $16M | $17M | $19M | $20M | $15M | $16M | $19M | $20M | $2M | $3M | $7M | $12M | $2M | |
| Capital Leases | $2M | $72.0K | $303.0K | $539.0K | $771.0K | $780.0K | $885.0K | $1M | $1M | $175.0K | $199.0K | · | · | · | $121.0K | · | |
| Other Non-current Liabilities | $70.0K | $1M | $1M | $1M | $1M | $1M | $7.0K | $2.0K | $47.0K | $48.0K | $49.0K | · | · | · | $55.0K | · | |
| Total Liabilities | $34M | $25M | $24M | $22M | $23M | $25M | $27M | $27M | $28M | $33M | $38M | $6M | $7M | $11M | $13M | $2M | |
| Common Stock | $106.0K | $91.0K | $91.0K | $91.0K | $91.0K | $87.0K | $86.0K | $85.0K | $85.0K | $85.0K | $77.0K | $37.0K | $37.0K | $37.0K | $64.0K | $31.0K | |
| Paid-in Capital | $241M | $175M | $172M | $167M | $161M | $138M | $136M | $134M | $134M | $133M | $68M | $385M | $385M | $385M | $33M | $400M | |
| Retained Earnings | $-138M | $-78M | $-68M | $-67M | $-70M | $-71M | $-73M | $-73M | $-74M | $-78M | $-86M | $-415M | $-413M | $-411M | $7M | $-370M | |
| AOCI | $1M | $586.0K | $-779.0K | $-2M | $-2M | $-2M | $-3M | $-946.0K | $-2M | $-2M | $-2M | · | · | · | $-392.0K | · | |
| Stockholders' Equity | $108M | $101M | $106M | $102M | $92M | $68M | $63M | $63M | $60M | $57M | $-16M | $4M | $-28M | $-26M | $43M | $29M | |
| Liabilities + Equity | $199M | $162M | $166M | $159M | $153M | $130M | $125M | $125M | $121M | $122M | $117M | $10M | $12M | $19M | $85M | $31M | |
| Shares Outstanding | 106,033,763 | 91,337,121 | 91,314,007 | 90,890,381 | 90,822,828 | 87,636,209 | 86,307,544 | 85,769,526 | 85,537,774 | 85,423,246 | 76,595,616 | 37,978,142 | 37,974,892 | 37,759,825 | 63,588,119 | 31,490,053 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $672.0K | $656.0K | $649.0K | $641.0K | $535.0K | $461.0K | $445.0K | $228.0K | $415.0K | $298.0K | $772.0K | $581.0K | $276.0K | $867.0K | $40.0K | |
| Stock-based Comp | $2M | $3M | $5M | $1M | $906.0K | $507.0K | $567.0K | $237.0K | $16.0K | $11.0K | $7M | $98.0K | $89.0K | $210.0K | $12M | $224.0K | |
| Amort. of Intangibles | $179.0K | $175.0K | $172.0K | $170.0K | $167.0K | $67.0K | $-80.5K | $10.0K | $8.5K | $100.0K | $-7.0K | $14.0K | $48.0K | $45.0K | · | · | |
| Other Non-cash | · | $10M | · | · | · | $-5M | · | · | · | $-7M | · | · | · | $-7M | · | · | |
| Operating Cash Flow | $-17M | $3M | $-6M | $5M | $2M | $-129.0K | $-3M | $2M | $-5M | $3M | $3M | $31M | $21M | $10M | $42M | $-7M | |
| CapEx | $262.0K | $178.0K | $144.0K | $668.0K | $256.0K | $122.0K | $-65.0K | $693.0K | $1M | $231.0K | $2M | $2M | $2M | $2M | · | · | |
| Investing Cash Flow | $10M | $-3M | $2M | $-1M | $-3M | $2M | $-2M | $-2M | $-8M | $-7M | $1M | $-26M | $-16M | $-8M | $-69M | $0 | |
| Stock Issued | · | · | · | · | $22M | $509.0K | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | · | · | · | $509.0K | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | · | $2M | $4M | $8M | · | · | |
| Financing Cash Flow | $-8.0K | $21.0K | $318.0K | $365.0K | $22M | $1M | $964.0K | $324.0K | $156.0K | $658.0K | $15M | $-1M | $-4M | $-8M | · | $-45M | |
| Net Change in Cash | $-6M | $431.0K | $-3M | $4M | $21M | $3M | $-4M | $-231.0K | $-14M | $-4M | $7M | $16M | $12M | $3M | $16M | $-52M | |
| Taxes Paid | · | $1M | $1M | $687.0K | $447.0K | $3M | $761.0K | $537.0K | $6M | $1M | $961.0K | $1M | $4M | $463.0K | · | · | |
| Free Cash Flow | · | $3M | · | · | · | $-251.0K | · | · | · | $3M | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | 94.7% | 95.7% | 96.0% | · | 96.2% | 97.0% | 96.4% | · | · | · | · | · | · | |
| Operating Margin | · | -41.5% | · | 22.7% | 8.1% | 10.3% | · | 16.6% | 12.9% | 29.7% | · | · | · | · | · | · | |
| Net Margin | · | -43.8% | · | 19.4% | 5.9% | 16.9% | · | 11.2% | 18.0% | 36.6% | · | · | · | · | · | · | |
| Pretax Margin | · | -41.0% | · | 25.0% | 8.4% | 21.0% | · | 15.4% | 23.9% | 45.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | -38.6% | · | 22.7% | 8.1% | 12.7% | · | 16.6% | 12.9% | 31.2% | · | · | · | · | · | · | |
| ROA | · | -6.8% | · | 4.2% | 1.1% | 3.0% | · | 4.2% | 6.8% | 14.1% | · | -7.7% | -5.2% | 0.88% | · | -8.9% | |
| ROE | · | -11.6% | · | 7.2% | 2.1% | 6.0% | · | 8.6% | 28.3% | 64.8% | · | -9.6% | -9.7% | 46.0% | · | -10.8% | |
| ROIC | · | -9.8% | · | 5.3% | 1.7% | 2.7% | · | 4.9% | 4.1% | 11.3% | · | -46.2% | 9.0% | -0.65% | · | · |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 4.6 | · | 6.2 | 5.4 | 3.6 | · | 3.7 | 3.4 | 3.2 | · | 2.9 | 2.7 | 2.0 | · | 18.4 | |
| Quick Ratio | · | 3.7 | · | 5.4 | 4.7 | 2.6 | · | 1.7 | 1.6 | 1.9 | · | 1.2 | 2.5 | 1.2 | · | 14.0 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.4 | 0.4 | 0.4 | · | · | · | · | · | · | |
| Inventory Turnover | · | 0.1 | · | · | 0.2 | 0.1 | · | 0.3 | 0.3 | 0.4 | · | · | · | · | · | · | |
| Receivables Turnover | · | 1.0 | · | 2.3 | 2.0 | 2.1 | · | · | · | · | · | · | · | · | · | · |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $1.11 | · | $1.12 | $1.01 | $0.78 | · | $0.74 | $0.71 | $0.66 | · | $0.09 | $-0.75 | $-0.69 | · | $0.93 | |
| Revenue / Share | · | $0.25 | · | $0.29 | $0.26 | $0.22 | · | $0.25 | $0.24 | $0.26 | · | · | · | · | · | · | |
| Cash Flow / Share | · | $0.03 | · | · | · | $-0.00 | · | · | · | $0.03 | · | · | · | $-0.16 | · | · | |
| Cash / Share | · | $0.41 | · | $0.44 | $0.40 | $0.17 | · | $0.18 | $0.19 | $0.35 | · | $0.06 | $0.18 | $0.21 | · | $0.73 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | · | · | · | $0.00 | $0.00 | $0.24 | · | $1.43 | |
| EPS (TTM) | $-0.22 | $-0.11 | · | $0.00 | $-0.02 | $0.02 | · | $-1.46 | $-1.42 | $-1.41 | · | $-0.89 | $-1.10 | $0.52 | · | $0.38 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $112M | $120M | · | $110M | $105M | $101M | · | $105M | $112M | $116M | · | · | · | · | · | · | |
| Net Income TTM | $-29M | $-16M | · | $9M | $6M | $13M | · | $-84M | $-79M | $-80M | · | $-12M | $-25M | $23M | · | $12M | |
| Market Cap | · | $637M | · | $678M | $668M | $677M | · | $1.08B | $1.02B | $1.49B | · | $273M | $199M | $119M | · | $236M | |
| P/E | -30.0 | -63.4 | · | · | -367.5 | 386.0 | · | -8.6 | -8.4 | -12.4 | · | -8.1 | -4.8 | 6.1 | · | 19.7 | |
| P/S | · | 5.3 | · | 6.2 | 6.3 | 6.7 | · | 10.2 | 9.1 | 12.9 | · | · | · | · | · | · | |
| P/B | · | 6.3 | · | 6.7 | 7.3 | 9.9 | · | 17.0 | 16.9 | 26.4 | · | 77.7 | -7.0 | -4.6 | · | 8.0 | |
| P / Tangible Book | 6.8 | 6.6 | · | 7.0 | 7.7 | 10.7 | · | 17.1 | 17.0 | 26.5 | · | 77.7 | · | · | · | 8.0 | |
| P / Cash Flow | · | 200.2 | · | · | · | -5244.6 | · | · | · | 517.8 | · | · | · | -19.1 | · | · | |
| Earnings Yield | -3.3% | -1.6% | · | 0.00% | -0.27% | 0.26% | · | -11.6% | -11.9% | -8.1% | · | -12.4% | -20.9% | 16.5% | · | 5.1% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | · | · | · | 2986.2% | · | · |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $117M | $106M | $113M | $102M | $7M |
| Margem Bruta % | · | 96.3% | 95.9% | · | · |
| Margem Operacional % | 9.8% | 15.3% | -59.3% | · | · |
| Lucro líquido | $10M | $18M | $-85M | $4M | $-88M |
| EPS Diluído | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 5.6 | 3.3 | 2.9 | 1.7 | · |
| Índice de Liquidez Seca | 4.6 | 2.4 | 1.7 | 1.3 | · |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-180.0K | $-6M | $17M | · | · |
Investidores institucionais (13F) 61 declarantes · $65.5M total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 11 (-4 vs trimestre anterior) | 7 (+4 vs trimestre anterior) | 31 (+13 vs trimestre anterior) | 9 (-2 vs trimestre anterior) | +5.3M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| HSG Holding Ltd | $24.714.470 | 3.750.299 | 37,75% | Ações |
| VANGUARD GROUP INC | $8.483.219 | 1.201.589 | 12,96% | Ações |
| BlackRock, Inc. | $6.550.085 | 993.943 | 10,01% | Ações |
| Octagon Capital Advisors LP | $6.289.601 | 954.416 | 9,61% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.778.949 | 876.927 | 8,83% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $3.513.176 | 532.950 | 5,37% | Ações |
| STATE STREET CORP | $1.617.199 | 245.402 | 2,47% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.214.445 | 184.286 | 1,86% | Ações |
| NORTHERN TRUST CORP | $1.117.249 | 169.537 | 1,71% | Ações |
| SBI Securities Co., Ltd. | $1.098.883 | 166.750 | 1,68% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $995.571 | 151.073 | 1,52% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $816.850 | 123.953 | 1,25% | Ações |
| GOLDMAN SACHS GROUP INC | $568.289 | 86.235 | 0,87% | Ações |
| Bank of New York Mellon Corp | $413.523 | 62.750 | 0,63% | Ações |
| MORGAN STANLEY | $274.743 | 41.691 | 0,42% | Ações |
| ALLIANCEBERNSTEIN L.P. | $171.392 | 24.590 | 0,26% | Ações |
| STRS OHIO | $170.022 | 25.800 | 0,26% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $166.516 | 25.268 | 0,25% | Ações |
| Nuveen, LLC | $161.488 | 24.505 | 0,25% | Ações |
| UBS Group AG | $123.649 | 18.763 | 0,19% | Ações |
| MILLENNIUM MANAGEMENT LLC | $121.836 | 18.488 | 0,19% | Ações |
| DEUTSCHE BANK AG\ | $118.218 | 17.939 | 0,18% | Ações |
| RHUMBLINE ADVISERS | $111.131 | 16.865 | 0,17% | Ações |
| WELLS FARGO & COMPANY/MN | $107.397 | 16.297 | 0,16% | Ações |
| FMR LLC | $98.679 | 14.974 | 0,15% | Ações |
| ROYAL BANK OF CANADA | $87.000 | 13.195 | 0,13% | Ações |
| BANK OF AMERICA CORP /DE/ | $82.539 | 12.525 | 0,13% | Ações |
| Polymer Capital Management (US) LLC | $77.630 | 11.780 | 0,12% | Ações |
| Vanguard Global Advisers, LLC | $65.788 | 9.983 | 0,10% | Ações |
| Police & Firemen's Retirement System of New Jersey | $59.382 | 9.011 | 0,09% | Ações |
| CITIGROUP INC | $56.582 | 8.586 | 0,09% | Ações |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $55.659 | 8.446 | 0,09% | Ações |
| JPMORGAN CHASE & CO | $50.510 | 7.831 | 0,08% | Ações |
| Russell Investments Group, Ltd. | $24.930 | 3.783 | 0,04% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $22.973 | 3.486 | 0,04% | Ações |
| BARCLAYS PLC | $21.273 | 3.228 | 0,03% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $17.793 | 2.700 | 0,03% | Ações |
| Tower Research Capital LLC (TRC) | $16.271 | 2.469 | 0,02% | Ações |
| Legal & General Group Plc | $13.536 | 2.054 | 0,02% | Ações |
| Ameritas Investment Partners, Inc. | $4.501 | 683 | 0,01% | Ações |
| Activest Wealth Management | $3.512 | 533 | 0,01% | Ações |
| Arax Advisory Partners | $1.621 | 246 | 0,00% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1.094 | 166 | 0,00% | Ações |
| Sterling Capital Management LLC | $1.061 | 161 | 0,00% | Ações |
| GAMMA Investing LLC | $962 | 146 | 0,00% | Ações |
| CWM, LLC | $725 | 104 | 0,00% | Ações |
| Physician Wealth Advisors, Inc. | $541 | 82 | 0,00% | Ações |
| Bare Financial Services, Inc | $521 | 79 | 0,00% | Ações |
| GoalVest Advisory LLC | $367 | 50 | 0,00% | Ações |
| OSAIC HOLDINGS, INC. | $288 | 44 | 0,00% | Ações |
Ativistas e proprietários de 5%+ 21 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Songjiang Ma, Yueying Zhu | 7 de Maio de 2026 | 6,33% | Emenda | M&A / venda | SEC |
| Ying Luo, Ping Lan | 6 de Maio de 2026 | 8,60% | Emenda | M&A / venda | SEC |
| GNI USA, Inc., GNI Group Ltd. ×4 declarações | 6 de Maio de 2026 | 69,10% | Emenda | M&A / venda | SEC |
| Ying Luo (“Mr. Luo”), Ping Lan | 6 de Setembro de 2024 | · | Declaração inicial | Investimento passivo | SEC |
| Songjiang Ma (“Mr. Ma”), Yueying Zhu | 6 de Setembro de 2024 | · | Declaração inicial | Investimento passivo | SEC |
| GNI Group Ltd., GNI Hong Kong Limited, GNI USA, Inc. ×2 declarações | 31 de Outubro de 2023 | · | Declaração inicial | · | SEC |
| JDS1, LLC, CCUR Holdings, Inc., CIDM II, LLC, Julian D. Singer, David S. Oros ×13 declarações | 7 de Outubro de 2022 | · | Declaração inicial | Investimento passivo | SEC |
| JEC II Associates, LLC, The Heidi S. Shippell-Heiland 2008 Irrevocable Trust, Michael Torok ×4 declarações | 22 de Setembro de 2022 | · | Declaração inicial | · | SEC |
| Julian Singer, JDS1, LLC 2, CCUR Holdings, Inc., David S. Oros ×3 declarações | 27 de Janeiro de 2022 | · | Declaração inicial | · | SEC |
| 22NW Fund, LP, 22 NW, LP, 22NW Fund GP, LLC, 22NW GP, Inc., Aron R. English ×2 declarações | 5 de Agosto de 2020 | · | Declaração inicial | · | SEC |
| CCUR Holdings, Inc., Wayne Barr, Jr., JDS1, LLC, David S. Oros, Julian Singer ×3 declarações | 17 de Janeiro de 2020 | · | Declaração inicial | · | SEC |
| Morgenthaler Management Partners VIII, LLC (“MMP VIII”), Morgenthaler Partners VIII, L.P. (“MP VIII”), Robert C. Bellas, Jr. (“Bellas”), Ralph E. Christoffersen (“Christoffersen”), John Lutsi (“Lutsi”), Gary J. Morgenthaler (“Morgenthaler”), Robert D. Pavey (“Pavey”), Gary R. Little (“Little”) | 14 de Fevereiro de 2018 | · | Declaração inicial | · | SEC |
| HealthCare Ventures VIII, L.P., HealthCare Partners VIII, L.P., HealthCare Partners VIII, LLC, James H. Cavanaugh, Ph.D., Harold R. Werner, John W. Littlechild, Christopher Mirabelli, Ph.D., Augustine Lawlor ×2 declarações | 9 de Fevereiro de 2018 | · | Declaração inicial | · | SEC |
| 23 de Maio de 2017 | · | Declaração inicial | · | SEC | |
| New Enterprise Associates 10, Limited Partnership, NEA Partners 10, Limited Partnership, Michael James Barrett, Peter J. Barris, Scott D. Sandell ×4 declarações | 29 de Março de 2017 | · | Declaração inicial | · | SEC |
| Essex Woodlands Health Ventures VIII, LLC, Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures Fund VIII, L.P., Jeff Himawan, Ph.D., James Currie, Martin Sutter, Immanuel Thangaraj, Petri Vainio, Ron Eastman, Steve Wiggins, Guido Neels | 31 de Agosto de 2015 | · | Declaração inicial | Investimento passivo | SEC |
| Morgenthaler Management Partners VIII, LLC, Morgenthaler Partners VIII, L.P., Ralph Christoffersen, Robert Bellas, John Lutsi, Gary Morgenthaler, Robert Pavey, Gary Little | 31 de Agosto de 2015 | · | Declaração inicial | Investimento passivo | SEC |
| Rosetta Capital V LP, Rosetta Capital V GP LP, Rosetta Capital V GP Limited, Rosetta Capital Limited | 28 de Agosto de 2015 | · | Declaração inicial | Investimento passivo | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BIOTECHNOLOGY VALUE FUND II, L.P., BVF INVESTMENTS, L.L.C., INVESTMENT 10, L.L.C., MSI BVF SPV, LLC, BVF PARTNERS, L.P., BFV INC., MARK N. LAMPERT ×6 declarações | 21 de Agosto de 2015 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 29 de Janeiro de 2008 | · | Declaração inicial | Investimento passivo | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 28 de Janeiro de 2008 | · | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 66 insiders · 26 diretores · 32 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Ying Luo | Chief Executive Officer | 8 de Junho de 2026 A | 2.565.226 | 0 | 2 | $-82.927 |
| Han Ying | Chief Executive Officer | 14 de Agosto de 2024 A | · | 0 | 0 | $0 |
| Charles C Wu | Chief Executive Officer | 20 de Novembro de 2023 A | · | 0 | 0 | $0 |
| Donald J Debethizy | President and CEO | 4 de Maio de 2012 A | 798 | 0 | 0 | $0 |
| Thomas Wilson Eastling | Chief Financial Officer | 4 de Maio de 2026 A | 15.000 | 0 | 0 | $0 |
| Ruoyu Chen | Chief Financial Officer | 7 de Janeiro de 2026 A | · | 0 | 0 | $0 |
| Seline E. Miller | SVP Finance; Interim CFO & PAO | 31 de Agosto de 2023 D | 0 | 0 | 0 | $0 |
| Clinton Musil | Chief Financial Officer | 8 de Fevereiro de 2021 A | · | 0 | 0 | $0 |
| Fletcher Payne | Chief Financial Officer | 12 de Agosto de 2019 A | 3.744 | 0 | 0 | $0 |
| Mauri K Hodges | Treasurer, CFO | 14 de Agosto de 2015 A | 1.159 | 0 | 0 | $0 |
| Alan A Musso | SVP, Fin+Admin, CFO & Treas | 17 de Outubro de 2014 A | 57.799 | 0 | 0 | $0 |
| Songjiang Ma | President | 28 de Maio de 2025 S | 2.806.084 | 0 | 0 | $0 |
| Weiguo Ye | Chief Operating Officer | 18 de Junho de 2026 M | 700.000 | 0 | 16 | $-869.947 |
| Joshua Benjamin Bergmann | GC and Corporate Secretary | 8 de Junho de 2026 A | · | 0 | 0 | $0 |
| Grant E. Blouse | Chief Scientific Officer | 9 de Agosto de 2022 P | 9.417 | 0 | 0 | $0 |
| Howard Levy | Chief Medical Officer | 9 de Agosto de 2021 P | 639 | 0 | 0 | $0 |
| Veronica Cai | Controller | 13 de Março de 2020 P | 7.353 | 0 | 0 | $0 |
| Edwin Madison | Chief Scientific Officer | 22 de Outubro de 2015 A | 31.008 | 0 | 0 | $0 |
| Patrick C. Rock | Secretary, GC | 14 de Agosto de 2015 A | 45.000 | 0 | 0 | $0 |
| Steven M. Toler | VP, Clin Pharm Sciences | 17 de Outubro de 2014 A | 46.000 | 0 | 0 | $0 |
| David A. Hosford | VP, Clin Dev & Reg Affairs | 23 de Janeiro de 2014 A | · | 0 | 0 | $0 |
| Karen A Hicks | VP, Human Resources | 17 de Janeiro de 2013 A | 0 | 0 | 0 | $0 |
| Peter A Zorn | SVP, Lgl Affrs, GC & Secretary | 17 de Janeiro de 2013 A | 0 | 0 | 0 | $0 |
| Merouane Bencherif | SVP and Senior Scien Fellow | 17 de Janeiro de 2013 A | 15.938 | 0 | 0 | $0 |
| William S Caldwell | SVP - Drug Discovery and Dev. | 20 de Setembro de 2011 G | 500 | 0 | 0 | $0 |
| Geoffrey C Dunbar | SVP, Clin. Dev. & Reg. Affairs | 29 de Março de 2011 A | 1.153 | 0 | 0 | $0 |
| Claire Weston | Conselheiro | 3 de Agosto de 2026 A | · | 0 | 0 | $0 |
| Maxwell Kirkby | Conselheiro | 3 de Agosto de 2026 A | · | 0 | 0 | $0 |
| Dan Weng | Conselheiro | 10 de Junho de 2026 A | · | 0 | 0 | $0 |
| Ping Zhang | Conselheiro | 10 de Junho de 2026 A | · | 0 | 0 | $0 |
| Rodney L Nussbaum | Conselheiro | 10 de Junho de 2026 A | · | 0 | 0 | $0 |
| Renate Parry | Conselheiro | 10 de Junho de 2026 A | · | 0 | 0 | $0 |
| Gordon Carmichael | Conselheiro | 10 de Junho de 2026 A | · | 0 | 0 | $0 |
| David M. Epstein | Conselheiro | 10 de Junho de 2026 A | · | 0 | 0 | $0 |
| Nassim Usman | Conselheiro | 28 de Junho de 2024 M | 1.636 | 0 | 0 | $0 |
| Andrea Hunt | Conselheiro | 31 de Agosto de 2023 D | 0 | 0 | 0 | $0 |
| Augustine Lawlor | Conselheiro | 31 de Agosto de 2023 D | 0 | 0 | 0 | $0 |
| Geoffrey Ling M.D. | Conselheiro | 7 de Janeiro de 2022 A | 31.790 | 0 | 0 | $0 |
| Eddie Williams | Conselheiro | 7 de Janeiro de 2022 A | 34.804 | 0 | 0 | $0 |
| Errol B Desouza | Conselheiro | 1 de Outubro de 2021 A | 29.801 | 0 | 0 | $0 |
| Jeanne Y Jew | Conselheiro | 9 de Setembro de 2021 A | · | 0 | 0 | $0 |
| Sharon Tetlow | Conselheiro | 9 de Junho de 2021 A | 3.635 | 0 | 0 | $0 |
| John P Richard | Conselheiro | 13 de Março de 2020 P | 3.716 | 0 | 0 | $0 |
| Stephen A Hill | Conselheiro | 6 de Setembro de 2018 D | 1.190 | 0 | 0 | $0 |
| Harold E Selick | Conselheiro | 16 de Janeiro de 2018 A | 16.614 | 0 | 0 | $0 |
| Jeff Himawan | Conselheiro | 20 de Agosto de 2015 J | 1.179.352 | 0 | 0 | $0 |
| Alan W Dunton | Conselheiro | 14 de Agosto de 2015 A | 10.000 | 0 | 0 | $0 |
| Charles A Blixt | Conselheiro | 14 de Agosto de 2015 A | 10.000 | 0 | 0 | $0 |
| Julia R Brown | Conselheiro | 14 de Agosto de 2015 A | 10.000 | 0 | 0 | $0 |
| SKALETSKY MARK B | Conselheiro | 7 de Junho de 2013 A | 11.332 | 0 | 0 | $0 |
| Steven Burrill | Conselheiro | 31 de Julho de 2012 M | 4.333 | 0 | 0 | $0 |
| Ralph Snyderman | Conselheiro | 7 de Junho de 2012 A | 0 | 0 | 0 | $0 |
| Ann Hanham | Conselheiro | 18 de Abril de 2006 C | 778.062 | 0 | 0 | $0 |
| GNI Hong Kong Ltd | Detentor de 10% | 27 de Outubro de 2023 J | 0 | 0 | 0 | $0 |
| Scott D. Sandell | Detentor de 10% | 5 de Dezembro de 2013 S | 0 | 0 | 0 | $0 |
| Peter J Barris | Detentor de 10% | 5 de Dezembro de 2013 S | 0 | 0 | 0 | $0 |
| James M Barrett | Detentor de 10% | 3 de Dezembro de 2013 M | 0 | 0 | 0 | $0 |
| Richard C Kramlich | Detentor de 10% | 19 de Novembro de 2012 X | 5.333 | 0 | 0 | $0 |
| NEA Partners 10, Limited Partnership | Detentor de 10% | 17 de Janeiro de 2008 J | 4.563.512 | 0 | 0 | $0 |
| Iii Eugene A Trainor | Detentor de 10% | 17 de Janeiro de 2008 J | 4.563.512 | 0 | 0 | $0 |
| New Enterprise Associates 10, Limited Partnership | Detentor de 10% | 17 de Janeiro de 2008 J | 4.563.512 | 0 | 0 | $0 |
| Mark W Perry | Detentor de 10% | 17 de Janeiro de 2008 J | 4.563.512 | 0 | 0 | $0 |
| Charles W Newhall III | Detentor de 10% | 17 de Janeiro de 2008 J | 4.563.512 | 0 | 0 | $0 |
| Peter Morris | Detentor de 10% | 6 de Fevereiro de 2007 M | 2.000 | 0 | 0 | $0 |
| Jeffrey P Brennan | · | 17 de Janeiro de 2013 A | 0 | 0 | 0 | $0 |
| Elaine V Jones | · | 29 de Novembro de 2007 X | 27.500 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 11 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IWO · iShares Trust | 0,01% | 120.729 SH | 11 de Setembro de 2026 | Diário |
| RSSL · Global X Funds | 0,00% | 8.775 NS | 31 de Julho de 2026 | N-PORT |
| IWM · iShares Trust | 0,00% | 387.159 SH | 11 de Setembro de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 238.693 SH | 19 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 614.654 SH | 19 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 104.607 SH | 19 de Agosto de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5.047 SH | 19 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13.494 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 805 SH | 19 de Agosto de 2026 | Diário |
| DFAS · Dimensional ETF Trust | 0,00% | 320 NS | 31 de Julho de 2026 | N-PORT |
| IWN · iShares Trust | · | 41.397 SH | 11 de Setembro de 2026 | Diário |
GYRE Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
Preço-alvo de 12 meses
3 analistas · 2026-10-02Alvo médio $18.67 +162,5%
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | · |
| ANNX | $750M | -3.7 | · | · | -100.7% | · |
| AVTX | $336M | -3.1 | -86.6% | -132642.4% | -83.4% | · |
| CADL | $310M | -7.8 | · | · | -53.7% | · |
| GERN | $845M | -10.2 | -60.2% | · | -34.4% | · |
| DSGN | $567M | -7.7 | · | · | -32.8% | · |
| FDMT | $432M | -3.1 | 230194.6% | -164.4% | -30.2% | · |
| ACHV | · | -4.0 | · | · | · | · |
| SLDB | $445M | -2.8 | · | · | -79.5% | · |
| FTH | · | · | · | · | · | · |
| VSTM | $600M | -2.6 | 209.1% | -677.6% | -449.2% | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.